Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 7/20 | 0.49 |
| ▸ | NTRK1 | P04629 | 7/20 | 0.49 |
| ▸ | AURKB | Q96GD4 | 4/20 | 0.49 |
| ▸ | PLK4 | O00444 | 2/20 | 0.46 |
| ▸ | PAK4 | O96013 | 2/20 | 0.46 |
| ▸ | JAK2 | O60674 | 3/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.42 |
| ▸ | CYP2C8 | P10632 | 3/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.42 |
| ▸ | JAK1 | P23458 | 3/20 | 0.42 |
| ▸ | TYK2 | P29597 | 3/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.42 |
| ▸ | JAK3 | P52333 | 3/20 | 0.42 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL174494 | 0.84 | PLK4 (0.46) | AURKANTRK1AURKBPLK4PAK4 | |
| SCHEMBL174820 | 0.81 | PLK4 (0.54) | AURKANTRK1AURKBPLK4PAK4 | |
| SCHEMBL168759 | 0.79 | NTRK1 (0.66) | AURKANTRK1AURKBJAK2CYP3A4 | |
| SCHEMBL165459 | 0.77 | ADORA2A (0.48) | ADORA3 | |
| SCHEMBL164012 | 0.76 | ADORA3 (0.43) | ADORA3 | |
| SCHEMBL174442 | 0.76 | PLK4 (0.66) | PLK4PAK4 | |
| SCHEMBL175070 | 0.74 | AURKA (0.63) | AURKANTRK1AURKBPLK4PAK4 | |
| SCHEMBL174053 | 0.74 | NTRK1 (0.50) | AURKANTRK1AURKBPLK4PAK4 | |
| SCHEMBL12105337 | 0.73 | DHODH (0.43) | AURKANTRK1AURKBPLK4PAK4 | |
| SCHEMBL173978 | 0.73 | NTRK1 (0.54) | AURKANTRK1AURKBPLK4PAK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130303533-A1 | AZOLOPYRIDINE AND AZOLOPYRIMIDINE COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATION (US) | 2013-11-14 | — | — | US | disclosed |
| EP-2611809-A1 | AZOLOPYRIDINE AND AZOLOPYRIMIDINE COMPOUNDS AND METHODS OF USE THEREOF | Ambit Biosciences Corporation (US) | 2013-07-10 | — | — | EP | disclosed |
| WO-2012030924-A1 | AZOLOPYRIDINE AND AZOLOPYRIMIDINE COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATION (US) | 2012-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130303533-A1 | AZOLOPYRIDINE AND AZOLOPYRIMIDINE COMPOUNDS AND METHODS OF USE THEREOF | JAK3, JAK2, JAK1 | AURKA 174/4885NTRK1 1619/4885AURKB 172/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.